Single- Arm Trial to Identify Potential Markers Underlying Variability in Response to Omalizumab (Xolair) Treatment in Atopic Dermatitis

Trial Profile

Single- Arm Trial to Identify Potential Markers Underlying Variability in Response to Omalizumab (Xolair) Treatment in Atopic Dermatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2014

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Atopic dermatitis
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms AMBITIOUS
  • Most Recent Events

    • 28 Apr 2014 New source identified and integrated (ClinicalTrials.gov).
    • 28 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top